Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BUB1 | O43683 | 1/20 | 0.42 |
| ▸ | ACLY | P53396 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.39 |
| ▸ | ABL1 | P00519 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | HCK | P08631 | 2/20 | 0.39 |
| ▸ | SRC | P12931 | 2/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.39 |
| ▸ | MTOR | P42345 | 2/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.39 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.39 |
| ▸ | PRKDC | P78527 | 2/20 | 0.39 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | FABP4 | P15090 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30711678 | 1.00 | BUB1 (0.42) | BUB1ACLYPIK3CDABL1EGFR | |
| SCHEMBL147532 | 0.89 | ACLY (0.46) | BUB1ACLYPIK3CDABL1EGFR | |
| SCHEMBL819797 | 0.88 | PIK3CD (0.46) | BUB1ACLYPIK3CDABL1EGFR | |
| SCHEMBL18805035 | 0.88 | PIK3CD (0.46) | BUB1ACLYPIK3CDABL1EGFR | |
| SCHEMBL30147588 | 0.84 | ACLY (0.43) | BUB1ACLYPIK3CDABL1EGFR | |
| SCHEMBL29820909 | 0.84 | HTR6 (0.46) | BUB1ACLYPIK3CDABL1EGFR | |
| SCHEMBL10193516 | 0.84 | BUB1 (0.40) | BUB1ACLYPIK3CDABL1EGFR | |
| SCHEMBL1373109 | 0.84 | HTR6 (0.46) | BUB1ACLYPIK3CDABL1EGFR | |
| SCHEMBL31424162 | 0.84 | ACLY (0.43) | BUB1ACLYPIK3CDABL1EGFR | |
| SCHEMBL23330949 | 0.83 | MAP2K4 (0.43) | BUB1ACLYPIK3CDABL1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3434668-B1 | INDOLO-SUBSTITUTED-PIPERIDINE COMPOUNDS AS ESTROGEN RECEPTOR DEGRADING AGENT | LUOXIN PHARMACEUTICAL SHANGHAI CO LTD (CN) | 2020-08-26 | — | — | EP | disclosed |
| US-10544095-B2 | 3-indol substituted derivatives, pharmaceutical compositions and methods for use | PFIZER INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190106414-A1 | SUBSTITUTED-INDOLE-COMPOUNDS AS ESTROGEN RECEPTOR DOWN-REGULATORS | Luoxin Healthcare Science and Technology Development (Beijing) Ltd. (CN) | 2019-04-11 | — | — | US | disclosed |
| EP-3434668-A1 | INDOLO-SUBSTITUTED-PIPERIDINE COMPOUNDS AS ESTROGEN RECEPTOR DEGRADING AGENT | Luoxin Biotechnology (Shanghai) Co., Ltd. (CN) | 2019-01-30 | — | — | EP | disclosed |
| US-20180222862-A1 | NOVEL 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | ITEOS THERAPEUTICS (BE) | 2018-08-09 | — | — | US | disclosed |
| US-9873690-B2 | 3-indol substituted derivatives, pharmaceutical compositions and methods for use | PFIZER INC (US) | 2018-01-23 | — | — | US | disclosed |
| US-20160272628-A1 | NOVEL 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | PFIZER INC. | 2016-09-22 | — | — | US | disclosed |
| EP-1358162-A1 | DIHYDROINDOLE AND TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002050041-A1 | DIHYDROINDOLE AND TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544095-B2 | 3-indol substituted derivatives, pharmaceutical compositions and methods for use | TDO2, IDO1, IDO2 | BUB1 3199/4885ACLY 1017/4885PIK3CD 1425/4885 |
| US-20180222862-A1 | NOVEL 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TDO2, IDO1, IDO2 | BUB1 3074/4885ACLY 1230/4885PIK3CD 1567/4885 |
| US-20190106414-A1 | SUBSTITUTED-INDOLE-COMPOUNDS AS ESTROGEN RECEPTOR DOWN-REGULATORS | ESR2, ESR1, GPER1 | BUB1 1535/4885ACLY 3844/4885PIK3CD 1332/4885 |
| US-20160272628-A1 | NOVEL 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TDO2, IDO1, IDO2 | BUB1 3074/4885ACLY 1230/4885PIK3CD 1567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.